Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from TempraMed Technologies Ltd. ( (TSE:VIVI) ) is now available.
TempraMed Technologies has begun rolling out its temperature-protection products across Super-Pharm, Israel’s largest pharmacy and health-retail chain, making its solutions more widely available to patients who rely on insulin, epinephrine auto-injectors, and other temperature-sensitive medications. The partnership significantly expands TempraMed’s reach in a key market with high prevalence of chronic conditions, boosts its visibility at the point of care, and strengthens its position as a category leader in personal medication temperature management.
The Super-Pharm rollout complements TempraMed’s broader multi-channel distribution strategy, which also targets global healthcare payors, HMOs, other national retail chains, and online direct-to-consumer platforms. Together with its recent rollout at Maccabi Pharm, the move enhances brand validation, supports sustained demand and repeat purchases, and serves as a strategic launchpad and proof-of-concept for further expansion into Europe, North America, and other high-growth regions.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical device company specializing in innovative, temperature-controlled storage solutions for life-saving, temperature-sensitive medications. Its patented, FDA-registered thermal insulation devices, including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, are designed to protect medications such as insulin and epinephrine without batteries or external power, supporting patients and healthcare providers across North America, Europe, and Asia.
Average Trading Volume: 54,105
For a thorough assessment of VIVI stock, go to TipRanks’ Stock Analysis page.